Cytokine zcytor17 ligand polynucleotides

• US 7,459,293 B2
• Filed: 12/13/2005
• Issued: 12/02/2008
• Est. Priority Date: 01/18/2002
• Status: Expired due to Fees

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Gross, Jane A., Sprecher, Cindy A., Hammond, Angela K., Grant, Francis J., Kuijper, Joseph L., Dasovich, Maria M.
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US11/301,764
• Publication Number:
  US 20060141579A1
• Time in Patent Office: 1,085 Days
• Field of Search: None
• US Class Current: 435/69.5
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims

1. An isolated polynucleotide molecule comprising the sequence of nucleotides that encode a polypeptide comprising the sequence of amino acid residues that is at least 95% identical to the sequence of amino acid residues of the polypeptide selected from the group consisting of:

(a) the polypeptide comprising the amino acid sequence from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO;

2;

(b) the polypeptide comprising the amino acid sequence from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO;

2;

(c) the polypeptide comprising the amino acid sequence from residues 24 (Thr) to 164 (Thr) as shown in SEQ ID NO;

2; and

(d) the polypeptide comprising the amino acid sequence from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO;

2

wherein the polypeptide induces proinflammatory cytokine production.

2. The isolated polynucleotide molecule of claim 1, wherein the nucleotides are selected from the group consisting of:

(a) a polynucleotide as shown in SEQ ID NO;

1 from nucleotide 139 to nucleotide 483;

(b) a polynucleotide as shown in SEQ ID NO;

1 from nucleotide 106 to nucleotide 519;

(c) a polynucleotide as shown in SEQ ID NO;

1 from nucleotide 97 to nucleotide 519; and

(d) a polynucleotide as shown in SEQ ID NO;

1 from nucleotide 28 to nucleotide 519.

3. The isolated polynucleotide of claim 1, wherein the amino acid residues as shown in SEQ ID NO:

2 at positions 72, 133, and 147 are cysteine.

4. The isolated polynucleotide of claim 1 wherein the sequence of amino acid residues has at least 96% sequence identity to:

(a) amino acid residues 38 to 152 as shown in SEQ ID NO;

2;

(b) amino acid residues 27 to 164 as shown in SEQ ID NO;

2;

(c) amino acid residues 24 to 164 as shown in SEQ ID NO;

2; and

(d) amino acid residues 1 to 164 as shown in SEQ ID NO;

2.

5. The isolated polynucleotide of claim 1 wherein the sequence of amino acid residues has at least 97% sequence identity to:

(a) amino acid residues 38 to 152 as shown in SEQ ID NO;

2;

(b) amino acid residues 27 to 164 as shown in SEQ ID NO;

2;

(c) amino acid residues 24 to 164 as shown in SEQ ID NO;

2; and

(d) amino acid residues 1 to 164 as shown in SEQ ID NO;

2.

6. The isolated polynucleotide of claim 1 wherein the sequence of amino acid residues has at least 98% sequence identity to:

(a) amino acid residues 38 to 152 as shown in SEQ ID NO;

2;

(b) amino acid residues 27 to 164 as shown in SEQ ID NO;

2;

(c) amino acid residues 24 to 164 as shown in SEQ ID NO;

2; and

(d) amino acid residues 1 to 164 as shown in SEQ ID NO;

2.

7. The isolated polynucleotide of claim 1 wherein the sequence of amino acid residues has at least 99% sequence identity to:

(a) amino acid residues 38 to 152 as shown in SEQ ID NO;

2;

(b) amino acid residues 27 to 164 as shown in SEQ ID NO;

2;

(c) amino acid residues 24 to 164 as shown in SEQ ID NO;

2; and

(d) amino acid residues 1 to 164 as shown in SEQ ID NO;

2.

8. The isolated polynucleotide of claim 1, wherein the sequence of amino acid residues comprises amino acid residues 38 to 152 as shown in SEQ ID NO:

2.

9. The isolated polynucleotide of claim 1, wherein the sequence of amino acid residues comprises amino acid residues 24 to 164 as shown in SEQ ID NO:

2.

10. The isolated polynucleotide of claim 1 wherein the polypeptide is produced in a prokaryotic cell.

11. The isolated polynucleotide of claim 10 wherein the polypeptide is produced in E. coli.

12. The isolated polynucleotide of claim 1 wherein the polypeptide is produced in a eukaryotic cell.

13. The isolated polynucleotide of claim 12 wherein the polypeptide is produced in a mammalian cell.

14. The isolated polynucleotide of claim 13 wherein the polypeptide is produced in a Chinese hamster ovary cell or in a baby hamster kidney (BHK) cell.

15. The isolated polynucleotide molecule of claim 1 comprising a sequence of nucleotides that encode a polypeptide said polypeptide further comprising an affinity tag.

16. The isolated polynucleotide molecule of claim 1 comprising a sequence of nucleotides that encode a polypeptide said polypeptide further comprising PEGylation.

17. An isolated polynucleotide molecule comprising the sequence of nucleotides that encode a polypeptide comprising at least 14 contiguous amino acid residues of SEQ ID NO:

2 wherein the polypeptide is used to produce an antibody.

18. An expression vector comprising the following operably linked elements:

(a) a transcription promoter;

(b) a DNA segment encoding a polypeptide comprising the amino acid sequence from residues 27 to 164 of SEQ ID NO;

2; and

(c) a transcription terminator.

19. An expression vector comprising the following operably linked elements:

(a) a transcription promoter;

(b) a DNA segment encoding a polypeptide comprising the sequence of amino acid residues that is at least 95% identical to residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO;

2 wherein the polypeptide induces proinflammatory cytokine production; and

(c) a transcription terminator.

20. A cultured cell comprising the expression vector according to claim 19.

21. A method of producing a protein comprising:

culturing a cell according to claim 20 under conditions wherein the DNA segment is expressed; and

recovering the protein encoded by the DNA segment.

22. An expression vector comprising the following operably linked elements:

(a) a transcription promoter;

(b) a DNA segment encoding a polypeptide comprising the amino acid residues 38 (Val) to 152 (Leu) of SEQ ID NO;

2; and

(c) a transcription terminator.

23. An isolated polynucleotide encoding a polypeptide comprising the sequence of amino acid residues from residue 27 to residue 164 as shown in SEQ ID NO:

2.

24. The isolated polynucleotide according to claim 23, wherein the polypeptide comprises the sequence of amino acid residues from residue 1 to residue 164 as shown in SEQ ID NO:

2.

25. The isolated polynucleotide of claim 23 wherein the polynucleotide comprises the sequence of nucleotides from nucleotide 106 to nucleotide 519 as shown in SEQ ID NO:

1.

26. The isolated polynucleotide of claim 25 wherein the polynucleotide comprises the sequence of nucleotides from nucleotide 1 to nucleotide 519 as shown in SEQ ID NO:

1.

27. An isolated polynucleotide encoding a polypeptide consisting of the sequence of amino acid residues from residue 27 to residue 164 as shown in SEQ ID NO:

2.

28. The isolated polynucleotide of claim 27 wherein the polynucleotide consists of the sequence of nucleotides from nucleotide 106 to nucleotide 483 as shown in SEQ ID NO:

1.

29. An isolated polynucleotide encoding a polypeptide consisting of the sequence of amino acid residues from residue 1 to residue 164 as shown in SEQ ID NO:

2.

30. The isolated polynucleotide of claim 29 wherein the polynucleotide consists of the sequence of nucleotides from nucleotide 1 to nucleotide 519 as shown in SEQ ID NO:

1.

31. An isolated polynucleotide encoding a polypeptide comprising the sequence of amino acid residues from residue 38 to residue 152 as shown in SEQ ID NO:

2.

32. The isolated polynucleotide of claim 31 wherein the polynucleotide comprises the sequence of nucleotides from nucleotide 139 to nucleotide 483 as shown in SEQ ID NO:

1.

33. The isolated polynucleotide of claim 31 wherein the polynucleotide consists of the sequence of nucleotides from nucleotide 139 to nucleotide 483 as shown in SEQ ID NO:

1.

34. An isolated polynucleotide comprising a sequence of nucleotides that encode an antigenic polypeptide comprising a sequence of 30 contiguous amino acid residues of SEQ ID NO:

2, wherein the antigenic polypeptide comprises the amino acid sequence selected from the group consisting of;

(a) amino acid residues 54 to 59 of SEQ ID NO;

2;

(b) amino acid residues 129 to 134 of SEQ ID NO;

2;

(c) amino acid residues 53 to 58 of SEQ ID NO;

2;

(d) amino acid residues 35 to 40 of SEQ ID NO;

2;

(e) amino acid residues 33 to 38 of SEQ ID NO;

2;

(f) amino acid residues 114 to 119 of SEQ ID NO;

2;

(g) amino acid residues 101 to 105 of SEQ ID NO;

2;

(h) amino acid residues 126 to 131 of SEQ ID NO;

2;

(i) amino acid residues 113 to 118 of SEQ ID NO;

2; and

(j) amino acid residues 158 to 162 of SEQ ID NO;

2

and wherein the polypeptide induces proinflammatory cytokine production.

35. The isolated polynucleotide of claim 34 comprising a sequence of nucleotides that encode an antigenic polypeptide comprising a sequence of 100 contiguous amino acid residues.